mmunoglobulin A nephropathy (IgAN) is one of the Materials and Methods most common glomerulopathies and may lead to renal failure in 20-40% of cases. Recurrent disease is common after
In this retrospective study, patient data between January 1990 transplantation and has been reported in 13-60% of patients. [1] and May 2004 were retrieved by the same person from the Initially considered a benign condition, graft losses from transplant records stored in the Department of Nephrology. recurrent IgAN have been reported over the last 20 years, Cases included in this study were those recipients whose native I casting doubt on the initial premise. [2] In a cohort of 487 patients with IgAN, we have shown that the disease in the Indian subcontinent has a relatively rapid rate of progression, with renal survival rates of 84, 55 and 33% at one, five and 10 years respectively. [3] Actuarial renal survival at 10 years in adults was between 80 and 85% in most of the European and Asian studies, but it was lower in studies from USA. [4] Renal transplant is an accepted modality of treatment for patients with end-stage IgAN. In the context of a malignant pretransplant phase and lack of data, the posttransplant course of IgAN in India remains speculative. In this single-center, retrospective analysis on 58 renal allograft recipients with IgAN as the cause of renal failure, we have aimed to study the actuarial graft survival compared to a reference group, the incidence and correlates of recurrent disease and graft loss after recurrence. kidney disease (NKD) was biopsy-proven IgAN. Data was gathered on donor status, recipient and donor HLA type, pretransplant length of disease, interval to recurrent disease after transplant, rejection episodes, posttransplant biopsies and graft loss.
Actuarial graft survival was compared to a reference group matched (2:1) for donor status, age at transplant, gender, date of transplant within two years and immunosuppression regimen. The reference group included those recipients whose NKD was lupus nephritis, chronic interstitial nephritis, focal segmental glomerulo-scelorosis and those with undetermined NKD. Those with diabetic nephropathy as NKD and recipients with clinical suspicion of end-stage renal disease (ESRD) due to IgAN were excluded from the reference group. gradually tapered to 10mg/day by the end of the sixth month. (67) 15 (16) 0.029 77 (84) azathioprine, in some cases, a few months after transplant. A Immunosuppression (conventional) 50 (86) 102 ( hematuria. The same policy for transplant biopsy was followed During the follow-up period, 19 grafts were lost in the entire throughout the study, while routine protocol biopsy was not cohort (n=174), six and 13 in the IgAN and the reference group performed. Recurrence of IgAN was diagnosed in patients who respectively. Cause of graft loss in patients with IgAN was had biopsy-proven IgAN as the cause of ESRD and the graft chronic allograft nephropathy in two (3.4%), noncompliance biopsy showed mesangial proliferation with predominant leading to chronic rejection in one (1.7%), de novo FSGS in deposition of IgA. Time of graft failure was defined as either one (1.7%) and sepsis with graft dysfunction in two (3.4%) the time of the recommencement of chronic dialysis or the patients. Mean graft survival time for recipients with IgAN time of the second transplant, whichever was earlier. Graft loss was 113.33 ± 10.4 months (95% CI: 93,134), with a five-year was attributed to recurrent IgAN when the renal histology ( w w w and 10-year graft survival of 90% and 49%, respectively. In the showed diffuse mesangial proliferative expansion and reference group the corresponding figures for mean graft glomerular sclerosis with IgA deposits. Related donors are survival, five-and 10-year graft survival were 100.2 ± 5 months donors who were genetically related to the recipients, which (95% CI: 90,110), 79% and 73%, respectively (P= 0.6), as shown included parent-child or sibling relationships. Nonrelated in Figure 1 . The mean graft survival time for the 42 related donors were either cadaver or spousal donors.
grafts (110 ± 12 months) was comparable (P= 0.6) to that seen in the 16 with unrelated (including cadaver) grafts (111 Statistical analysis ± 13 mo). Five-year graft survival for those with related donors Data are expressed as means ± SD and were analyzed by was 95%, while in those with unrelated donors it was 80%.
Immunosuppression Most of the recipients received cyclosporine (CsA), prednisolone and azathioprine as part of the triple regimen. 
Results
During the study period, 1460 renal transplants were performed at the institute. The ESRD due to biopsy-proven IgAN was the primary diagnosis in 56 patients (58 renal transplants). Reference group included 116 recipients. The demographic data for the IgAN and reference groups were essentially comparable, save for HLA B mismatch [ Table 1 ].
IgA in the graft
During a mean follow-up of 42 months (range, 1-144 months), 28 event graft biopsies were performed in 20 grafts. In five of the 20 (25%) grafts biopsied, recurrence IgAN as evidenced by mesangial IgA deposition with or without mesangial hypercellularity was documented after a mean duration of 28 months. Pathologically, the recurrence in three patients was isolated, but in the other two patients, recurrences were accompanied by varying degrees of chronic rejection. The cumulative incidence of recurrence in patients who had undergone event renal biopsies by different indications was 25%. Although it would have required protocol biopsies of all 58 grafts to clearly determine the prevalence of recurrence, we could state that 20 (34%) of 58 grafts had clinically apparent recurrence. Recurrence of disease did not correlate for nearly 20% of patients with end-stage renal disease and characterized by a highly variable clinical course; ranging from a benign condition to one with a rapidly progressive course.
[4]
In India, IgAN seems to have a relatively poor prognosis with five-and 10-year renal survival rates being 55 and 33%, 88 ± 6 mo (95% CI: 75,100), with a five-year graft survival of 100% (P= 0.4 documented in five grafts (not included in this study) whose native kidney disease was undetermined. Whether these constituted recurrence or de novo disease, one could never tell as the NKD was undetermined.
Discussion
IgAN is the most common form of primary GN, accounting respectively.
[3] Figure 1 : Actuarial graft survival analysis for IgA nephropathy (solid line) and reference group (broken line) P= 0.6, log rank test
The overall graft survival in the IgA group seen in this study was not significantly different from that in the reference group. with recipient sex, age at transplant, immunosuppression,
The similarity in results for IgA and nonIgA renal transplant donor status or specific HLA antigens [ Table 2 ]. However, recipients confirms the results of a multicenter analysis that the recurrence group had a significantly greater degree of indicated that graft survival rates in IgA transplant recipients proteinuria at last follow-up, when compared to the were better than in the general transplant population. [5] The nonrecurrence group (P= 0.018). Similarly, graft loss in potential role of immunologic dysfunction that includes the patients with recurrent disease tended to be higher than those effects of the high level of IgA anti-HLA antibody in IgAN without, but not achieving statistical significance. (P= 0.07).
patients has been speculated as the mechanism for superior graft survival among patients with IgAN. [5] Mean graft survival time for recipients with IgAN and recurrence was 80 ± 32 mo (95% CI: 17,143), with a five-year Berger et al were the first to describe the recurrence of IgAN graft survival of 66%, while in the nonrecurrence group it was and subsequent studies showed 20-60% incidences of recurrence after renal transplantation.
[1] 5% will have lost their graft as a result of recurrent IgAN. [1] Histological recurrence in this study occurred in 25% (five of 20) of the grafts, as opposed to an incidence of 30-61% in other series. [1] As alluded to before, the varying indications for biopsy and the absence of protocol biopsies is a limiting factor while making comparisons. The overall incidence of recurrent disease in this study may have been underestimated because biopsies were undertaken only when prompted by clinical abnormalities.
The predictors of clinically relevant recurrent IgAN after a renal transplant, represents largely a function of time posttransplantation and cannot be predicted by other variables, [1] which is in accordance with the results of this study. Nevertheless, when compared to the nonrecurrence group, the recurrence group had a significantly greater degree of proteinuria (P= 0.018) and a trend for graft loss (P= 0.07). ) .
